ecancermedicalscience

Research

Outcomes following CyberKnife robotic radiosurgery for pituitary adenomas—a large single-centre study

28 Nov 2024
Kamran Saeed, Kaynat Siddiqui, Hafiza Fatima Aziz, Fatima Shaukat, Shazia Kadri, Aneeta Ghulam Muhammad, Aneela Darbar, Tariq Mahmood

Introduction: The role of stereotactic radiosurgery (SRS) in pituitary adenomas (PAs) is evolving especially considering its safety. Existing literature is hampered by limited sample sizes and short-term follow-ups, impeding its preeminence in the clinical and radiological outcomes. We propose a comprehensive, single-centred study to evaluate the outcomes following CyberKnife stereotactic radiosurgery (CK SRS) for PAs in a larger patient population, incorporating meticulous clinical and radiological follow-up.

Methods: This is a retrospective cohort study of 278 cases of PAs that underwent CK SRS from 2013 to 2021. Based on their endocrinology profile, they were classified as functional adenomas (FA) and non-functional adenomas (NFA). We assessed pre and post-CK SRS clinical, visual, hormonal and radiological parameters and the associated toxicity. Where applicable, data were compared using the Independent t-test, chi-square test, Fisher Exact and Mann-Whitney U test. A p-value <0.05 was considered significant.

Results: The median age of the patients was 40.13 ± 12.61 years (111 female and 167 male patients). The median prescribed radiosurgery dose was 25.0 ± 5.0 Gy into 3 or 5 fractions. The median follow-up time was 12 months (IQR 20). Data were grouped into NFA (169, 60.8%) and FA (109, 39.2%). After adjusting for patients lost to follow-up, post-CK SRS visual perimetry improved in 80.4% of patients and tumour size reduced in 78.6% of the study population. Seventeen patients with NFA and nine with FA manifested new-onset hormonal deficiencies. No statistically significant differences were seen in post-CK SRS visual outcomes and hormone deficiency groups.

Conclusion: CK SRS is effective and safe for managing PAs, achieving tumour control and preserving visual function with minimal toxicity. Extended follow-up is needed to evaluate post-SRS toxicity and hypopituitarism.

Related Articles

Amanda Acioli de Almeida Robatto, Erika Andrade Rocha, Renata Colombo Bonadio, Denis Artico Galhera, Carolina Teixeira Muratori, Admir Andre Belo Bueno, Abraão Ferreira Lopes Dornellas, Luciana Bastos Valente Alban, Carolina Ribeiro Victor, Maria Ignez Freitas Melro Braghiroli, Marília Polo Mingueti e Silva, Camila Soares Araujo, Carlos Frederico Sparapan Marques, Caio Sergio Rizkallah Nahas, Karim Yaqub Ibrahim, André Tsin Chih Chen, Paulo Marcelo Gehm Hoff, Camila Motta Venchiarutti Moniz
F Z Abdelli, S Ouaddane Alami, S Khalfi, K Soussy, W Hassani, F Z Farhane, Z Alami, T Bouhafa
Jeanine Justiniano, Ally H Mwanga, Daniel W Kitua, Nashivai E Kivuyo, Seif Wibonela, Cameron E Gaskill
Joaquin Fernandez-Alberti, Alex R Villaalta López, Guillermo Scolari, Alejandro Iotti, Marcelo Featherston
Bharath B Gangadharaiah, Ghazal Tansir, Sameer Rastogi, Simran Kaur, Vikas Garg, Ekta Dhamija, Adarsh Barwad, Shivanand Gamanagatti, Sandeep Bhoriwal, Maroof A Khan